You are here

A Rapid assay for RNA targeted drugs: Instrumentation Supplement

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42GM097917-02A1
Agency Tracking Number: R42GM097917
Amount: $1,430,141.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA14-077
Timeline
Solicitation Year: 2017
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-07-10
Award End Date (Contract End Date): 2017-06-30
Small Business Information
900 B West Faris Road, Greenville, SC, 29605
DUNS: 831389122
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DEV ARYA
 (864) 656-1106
 dparya@clemson.edu
Business Contact
 DEV ARYA
Phone: (864) 455-5341
Email: dev.arya@nubadllc.com
Research Institution
 CLEMSON UNIVERSITY
 CLEMSON, SC, 29634-0001
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics and account for three of the top five classes of antibiotics The crisis of antibiotic resistance has resulted in a significant cost both financially and in human life Seveny percent of infectious bacteria are resistant to at least one commonly used antibiotic treatment NIH In the United States alone million people get an infection while in a hospital environment with just under of these cases resulting in death NIH This situation demonstrates the increased need for the development of new antibiotic therapies A rapid assay examining the binding affinity of novel aminoglycosides to the A site and other nucleic acid sites will facilitate the discovery of effective therapies In Phase I we have developed a fluorescence based competition assay using a base RNA model of the ribosomal A site and a novel fluorescent reporter molecule F neo This assay is readily adaptable to a high throughput format as larger compound libraries are established In Phase II our specific aims are develop an automated fluorescent based assay for screening broad based RNA targets This aim includes expanding the current assay to a high throughput automated screen and adapting the assay to include other nucleic acid drug targets Expand the library of aminoglycoside conjugated molecules Phase I resulting in a small in house compound library that was screened using the assay developed in Phase I In Phase II the library will be greatly expanded by the conjugation of aminoglycosides with different classes of compounds using a variety of linker lengths and types Screening of NUBAD compounds to determine and characterize the activity This in vivo assay will help establish a correlation between andquot hitsandquot from the assay and activity in the cell At the conclusion of this work we will have established a commercially available assay for the high throughput screening of compounds that target nucleic acids This technology will fill a niche in the high throughput screening industry and result in more efficien development of compounds that treat disease related to nucleic acid therapies PUBLIC HEALTH RELEVANCE Some of the most significant therapies that treat disease target nucleic acids A rapid assay examining the binding affinity of nucleic acid will facilitate he discovery of effective therapies At the conclusion of this work we will have established a commercially available assay for the high throughput screening of compounds that target nucleic acids This technology will fill a niche in the high throughput screening industry and result in more efficient development of compounds that treat disease related to nucleic acid therapies

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government